Evonik Health Care vs FUJIFILM Diosynth Biotechnologies: CDMO Comparison

How does Evonik Health Care compare to FUJIFILM Diosynth Biotechnologies for mRNA/LNP manufacturing?

Side-by-side comparison of Evonik Health Care and FUJIFILM Diosynth Biotechnologies on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Birmingham, AL · Vancouver, BC
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
2
— NAI / VAI / OAI
1 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
2
Clinical programs (matched)
0
Capacity
—
Modalities
mRNA, Biologics
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score
85/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
29
MHRA GMP certificates (compliant)
6
Clinical programs (matched)
0
Capacity
Expanding
Modalities
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Key differences

  • Evonik Health Care has FDA inspections on record (2); FUJIFILM Diosynth Biotechnologies does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates; Evonik Health Care does not appear in EudraGMDP.
  • FUJIFILM Diosynth Biotechnologies has stronger MHRA / UK coverage (6 compliant certificates vs 2).

On a 13-modality CDMO landscape, both Evonik Health Care and FUJIFILM Diosynth Biotechnologies qualify as mRNA/LNP manufacturers; FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score for mRNA/LNP programs in this comparison.

What to evaluate for mRNA/LNP programs

Both Evonik Health Care and FUJIFILM Diosynth Biotechnologies qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

IVT mRNA synthesis

Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.

LNP formulation

LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.

Plasmid / starting material

mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.

Cold chain & stability

mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

See all mRNA/LNP CDMOs ranked by Signal Score →

Frequently asked: Evonik Health Care vs FUJIFILM Diosynth Biotechnologies

How does Evonik Health Care compare to FUJIFILM Diosynth Biotechnologies for mRNA/LNP manufacturing?

On CDMO Signal's composite Signal Score, Evonik Health Care is 82/100 and FUJIFILM Diosynth Biotechnologies is 85/100; Evonik Health Care has 2 FDA inspections on record vs 0 for FUJIFILM Diosynth Biotechnologies; European coverage is 2 active EMA+MHRA certificates for Evonik Health Care vs 35 for FUJIFILM Diosynth Biotechnologies. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Evonik Health Care or FUJIFILM Diosynth Biotechnologies?

Both Evonik Health Care and FUJIFILM Diosynth Biotechnologies maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Evonik Health Care has 2 FDA inspections on record; FUJIFILM Diosynth Biotechnologies has 0.

How do Evonik Health Care and FUJIFILM Diosynth Biotechnologies compare on European GMP coverage?

Evonik Health Care holds 0 active EMA GMP certificates and 2 MHRA / UK certificates. FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for mRNA/LNP manufacturing — Evonik Health Care or FUJIFILM Diosynth Biotechnologies?

Both Evonik Health Care and FUJIFILM Diosynth Biotechnologies are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Evonik Health Care carries a Signal Score of 82/100 and FUJIFILM Diosynth Biotechnologies carries 85/100 — essentially tied for FUJIFILM Diosynth Biotechnologies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Evonik Health Care and FUJIFILM Diosynth Biotechnologies for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.